Biologics
Pharmaceuticals

Vor Bio completes UPSTREAM MG enrolment and launches oMG trial

Vor Bio has fully enrolled its global Phase 3 gMG study and will initiate a sister trial in ocular myasthenia gravis, with topline data expected
Vor Bio has fully enrolled its global Phase 3 gMG study and will initiate a sister trial in ocular myasthenia gravis, with topline data expected
The Biotech Times Editorial Team  · 
Biologics
Pharmaceuticals

Korsana Biosciences lists on Nasdaq after $380m raise

The Waltham-based neurodegenerative disease biotech completed its merger with Cyclerion and a $380m private placement, beginning Nasdaq trading under "KRSA" on 9
The Waltham-based neurodegenerative disease biotech completed its merger with Cyclerion and a $380m private placement, beginning Nasdaq trading under "KRSA" on 9
The Biotech Times Editorial Team  · 
Pharmaceuticals
Biologics

Novo Nordisk: semaglutide clears obesity threshold in 40% of children

Phase 3 STEP Young data show 40.4% of children aged 6 to 11 treated with semaglutide dropped below the obesity BMI threshold after 68
Phase 3 STEP Young data show 40.4% of children aged 6 to 11 treated with semaglutide dropped below the obesity BMI threshold after 68
The Biotech Times Editorial Team  · 
Pharmaceuticals
Regulatory Science

Aprea Therapeutics expands patent estate for WEE1 and ATR programmes

The Nasdaq-listed oncology company has detailed patents covering APR-1051 and ATRN-119, with WEE1 protection potentially running to 2047.
The Nasdaq-listed oncology company has detailed patents covering APR-1051 and ATRN-119, with WEE1 protection potentially running to 2047.
The Biotech Times Editorial Team  · 
Pharmaceuticals
Biologics

Ascendis to present infant achondroplasia data at ESPE 2026

Ascendis Pharma will share sentinel cohort data from its reACHin pivotal trial of navepegritide in infants under two at ESPE 2026.
Ascendis Pharma will share sentinel cohort data from its reACHin pivotal trial of navepegritide in infants under two at ESPE 2026.
The Biotech Times Editorial Team  · 
Medical Devices
Diagnostics

BTT Medical opens first-in-human trial of fever-induction device

BTT Medical Institute has launched a safety trial of its brain-guided hyperthermia system, citing a single ALS case report as the basis for development.
BTT Medical Institute has launched a safety trial of its brain-guided hyperthermia system, citing a single ALS case report as the basis for development.
The Biotech Times Editorial Team  · 
Medical Devices

Lakeland Fire + Safety wins second GFS foul weather gear contract

Lakeland's Hong Kong subsidiary has secured a follow-on contract to supply flame-resistant foul weather suits to Hong Kong Government Flying Service pilots
Lakeland's Hong Kong subsidiary has secured a follow-on contract to supply flame-resistant foul weather suits to Hong Kong Government Flying Service pilots
The Biotech Times Editorial Team  · 
Biologics
Pharmaceuticals

NorthStrive files patents for EL-22 and EL-32 in spaceflight muscle loss

NorthStrive Biosciences has filed two US patent applications extending its myostatin-targeting probiotic candidates into microgravity-induced muscle atrophy.
NorthStrive Biosciences has filed two US patent applications extending its myostatin-targeting probiotic candidates into microgravity-induced muscle atrophy.
The Biotech Times Editorial Team  · 
Biologics
Pharmaceuticals

Novartis HARBOR Phase III trial misses primary endpoint in DM1

Del-desiran failed to improve hand myotonia in a 150-patient Phase III study, though secondary endpoints showed signs of clinical activity.
Del-desiran failed to improve hand myotonia in a 150-patient Phase III study, though secondary endpoints showed signs of clinical activity.
The Biotech Times Editorial Team  · 
Pharmaceuticals

Teva launches senior notes offering to refinance existing debt

Teva Pharmaceutical is issuing EUR and USD senior notes via Dutch finance subsidiaries, with proceeds earmarked primarily for early redemption of existing notes.
Teva Pharmaceutical is issuing EUR and USD senior notes via Dutch finance subsidiaries, with proceeds earmarked primarily for early redemption of existing notes.
The Biotech Times Editorial Team  · 
Medical Devices

Nyxoah enrols first patient in BREATHE post-approval OSA study

The Belgian medtech has begun a 229-patient, five-year US real-world study of its Genio bilateral hypoglossal nerve stimulator, approved by the FDA
The Belgian medtech has begun a 229-patient, five-year US real-world study of its Genio bilateral hypoglossal nerve stimulator, approved by the FDA
The Biotech Times Editorial Team  · 
Pharmaceuticals
Diagnostics

Zentalis Pharmaceuticals launches share offering for azenosertib

Zentalis is raising fresh capital via an underwritten public offering to fund trials and pre-commercial activities for its WEE1 inhibitor azenosertib in ovarian cancer.
Zentalis is raising fresh capital via an underwritten public offering to fund trials and pre-commercial activities for its WEE1 inhibitor azenosertib in ovarian cancer.
The Biotech Times Editorial Team  · 
Subscribe to